Neutralizing and non-neutralizing antibody responses in HIV-1 subtype C chronically infected patients with divergent rates of disease progression per Archary, D, Rong, R, Gordon, M, Boliar, S, Gray, E, Dugast, A, Hermanus, T, Goulder, P, Coovadia, H, Morris, L, Alter, G, Derdeyn, C, Ndung'u, T

Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. per Archary, D, Rong, R, Gordon, M, Boliar, S, Madiga, M, Gray, E, Dugast, A, Hermanus, T, Goulder, P, Coovadia, H, Werner, L, Morris, L, Alter, G, Derdeyn, C, Ndung'u, T

Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection per Archary, D, Rong, R, Gordon, M, Boliar, S, Madiga, M, Gray, E, Dugast, A, Hermanus, T, Goulder, P, Coovadia, H, Werner, L, Morris, L, Alter, G, Derdeyn, C, Ndung'u, T

Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity per Ackerman, M, Crispin, M, Yu, X, Baruah, K, Boesch, A, Harvey, D, Dugast, A, Heizen, E, Ercan, A, Choi, I, Streeck, H, Nigrovic, P, Bailey-Kellogg, C, Scanlan, C, Alter, G